Bio Rad Labs INC (BIO) Shareholder Levin Capital Strategies LP Increased Stake

Bio-Rad Laboratories, Inc. (NYSE:BIO) Corporate LogoDuring 2018 Q4 the big money sentiment decreased to 1.01. That’s change of 0.06, from 2018Q3’s 1.07. 38 investors sold all, 95 reduced holdings as BIO ratio dropped. 94 increased holdings while 40 funds amassed holdings. Funds hold 19.66 million shares thus 10.88% more from 2018Q3’s 17.73 million shares. Cohen Cap Mgmt Inc invested in 900 shs or 0.06% of the stock. Trexquant Ltd Partnership invested in 1,298 shs or 0.02% of the stock. Us State Bank De owns 0% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 4,356 shs. Moreover, Captrust Advisors has 0% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 6 shs. Mason Street Advsrs Ltd Liability Corporation has 10,548 shs for 0.06% of their capital. Royal London Asset Mngmt Ltd reported 11,645 shs or 0.02% of all its holdings. 15 were reported by Howe And Rusling Inc. Utah Retirement reported 3,971 shs. Cwm Ltd Limited Liability Company stated it has 102 shs. 2,970 are owned by Btr Inc. Legal General Group Public Ltd Company, United Kingdom-based fund reported 29,252 shs. Fmr Ltd Liability Corporation invested in 0.01% or 162,202 shs. Parametric Portfolio Associate Ltd Limited Liability Company reported 80,618 shs. State Of Wisconsin Invest Board holds 4,055 shs or 0% of its capital. Cramer Rosenthal Mcglynn Limited Company invested in 1.18% or 200,656 shs.

BIO registered $1.27 million net activity with 0 insider purchases and 4 insider sales since December 11, 2018. On Tuesday, December 11 the insider TUMOLO ANNETTE sold $604,704. On Friday, December 14 $97,228 worth of Bio-Rad Laboratories, Inc. (NYSE:BIO) was sold by Crowley Michael. On Friday, December 14 TSINGOS CHRISTINE A had sold 1,411 shs worth $349,928.

Levin Capital Strategies Lp’s stake in Bio Rad Labs Inc (BIO) is increased by 7126.16% based on its latest 2018Q4 regulatory filing with the SEC. By buying 561,328 shares Levin Capital Strategies Lp made the stock popped up with 13.85%. At the end of 2018Q4, the 569,205 shares of the capital goods company held by the hedge fund were priced at $132.18 million, up from 7,877 at the end of the previous reported quarter. $9.14B is Bio Rad Labs Inc’s MC. BIO hit $306.99 during the last trading session after $0.61 change.Bio-Rad Laboratories, Inc. has volume of 41,919 shares. Since April 11, 2018 BIO has risen 18.11% and is uptrending. BIO outperformed by 13.74% the S&P500.

About $8.28 billion and $4.54 billion US Long portfolio Levin Capital Strategies Lp manages. Its stake in Occidental Pete Corp Del (NYSE:OXY) was decreased by 175,644 shares to 3.19M shares valued at $195.77M in 2018Q4, according to the filing. Levin Capital Strategies Lp has cut its stake in Fluidigm Corp Del (NASDAQ:FLDM) and also reduced its holding in Xcel Energy Inc (NYSE:XEL) by 336,681 shares in the quarter, for a total of 907,265 shares.

For more Bio-Rad Laboratories, Inc. (NYSE:BIO) news published briefly go to: Seekingalpha.com, Seekingalpha.com, Benzinga.com, Seekingalpha.com or Benzinga.com. The titles are as follows: “New operating chief at Arcus Bio – Seeking Alpha” published on March 25, 2019, “BTIG likes Arcus Bio in premarket analyst action – Seeking Alpha” on March 18, 2019, “41 Stocks Moving In Friday’s Mid-Day Session – Benzinga” with a publish date: March 22, 2019, “Emergent Bio launches late-stage study of AV7909 – Seeking Alpha” and the last “35 Stocks Moving In Thursday’s Pre-Market Session – Benzinga” with publication date: March 14, 2019.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Ratings Coverage

A total of 3 analysts rate Bio-Rad Laboratories (NYSE:BIO) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Š¢herefore 100% are bullish. (NYSE:BIO) has 7 ratings reports on 11 Apr 2019 according to StockzIntelligence. In Friday, March 1 report Deutsche Bank maintained the stock with “Buy” rating. On Friday, March 1 the company was maintained by Barclays Capital. On Friday, November 2 Barclays Capital maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) with “Equal-Weight” rating. On Thursday, January 3 the firm has “Overweight” rating given by Barclays Capital.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.